Fusion Antibodies (LSE:FAB) Total Stockholders Equity: £0.73 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:FAB Fusion Antibodies PLC LSE:FAB
19 GF Score
Price £0.13
GF Value £0.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fusion Antibodies Total Stockholders Equity?

Fusion Antibodies LSE:FAB -6.67% 19 Total Stockholders Equity is £0.73 Mil as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 19/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Fusion Antibodies's Total Stockholders Equity for the quarter that ended in Sep. 2025 was £0.73 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Fusion Antibodies's Book Value per Share for the quarter that ended in Sep. 2025 was £0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Fusion Antibodies's Debt-to-Equity for the quarter that ended in Sep. 2025 was 0.53.

Fusion Antibodies  (LSE:FAB) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Fusion Antibodies's Book Value per Share for the quarter that ended in Sep. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.726-0)/113.656
=0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Fusion Antibodies's Debt-to-Equity for the quarter that ended in Sep. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.105 + 0.283) / 0.726
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Total Stockholders Equity Related Terms

Fusion Antibodies Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Total Stockholders Equity Chart

Fusion Antibodies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.75 3.68 1.12 1.79 0.67

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.79 1.06 0.67 0.73
LSE:FAB
19GF Score
Fusion Antibodies PLC LSE:FAB
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of £0.73 Mil mean?
Fusion Antibodies (LSE:FAB) has a Total Stockholders Equity of £0.73 Mil as of Sep. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Fusion Antibodies and its competitors.
Is Fusion Antibodies' Total Stockholders Equity too high?
Fusion Antibodies' current Total Stockholders Equity is £0.73 Mil. Overall, Fusion Antibodies has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Total Stockholders Equity compare to VRTX and REGN?
Fusion Antibodies' Total Stockholders Equity of £0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Fusion Antibodies and its competitors. Fusion Antibodies's current Total Stockholders Equity is £0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.13 — trading 212.5% above its estimated fair value. The current Total Stockholders Equity is £0.73 Mil. Fusion Antibodies' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Total Stockholders Equity is £0.73 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.13 is trading 212.5% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

  • Total Stockholders Equity: £0.73 Mil
  • GF Value™: £0.04 vs. price of £0.13 (212.5% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
19GF Score

Get the complete analysis for LSE:FAB

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.13
Price
£0.04
GF Value